Tackling the Diabetes Epidemic through a Population Impact Approach
Jan Hux is the President and CEO of Diabetes Canada. Canadians have been at the forefront of tackling diabetes since the discovery of insulin. Now that the disease has become…
Pediapharm is the first and only speciality pharmaceutical corporation in Canada that exclusively distributes and licenses innovative medicines used to treat pathological conditions that mainly affect children from infancy to eighteen years of age.
Through its network with key stakeholders within the paediatric arena, Pediapharm’s key objective is to partner with leading healthcare entities around the world to bring innovative paediatric products to the Canadian market. By doing so, the company contributes to the improvement of children’s health and quality of life; its partners can thus be assured of long-term commitment and unwavering integrity.
Pediapharm’s unique business model, company values and human capital, set it apart as Canada’s leading paediatric speciality pharmaceutical company.
Contact:
Address: 1 Place du Commerce, Verdun, QC H3E 1A2 Montreal, Canada
Tel.: +1 514 762 2626
Website: http://www.pedia-pharm.com/en/
Jan Hux is the President and CEO of Diabetes Canada. Canadians have been at the forefront of tackling diabetes since the discovery of insulin. Now that the disease has become…
Brian Hilberdink, President of Novo Nordisk Canada, calls for collaboration between government and industry to ensure that Canadian patients get swift access to the best treatments. As a Canadian who…
John Fowler founded 7ACRES, a licensed producer of cannabis, in 2013. In 2014, 7ACRES went over to become part of The Supreme Cannabis Company, which today stands as a unique…
Mark Ware, the Chief Medical Officer of Canopy Growth Corporation, has intensely investigated the effects of cannabinoids, making him perfectly placed to cover this new era of cannabis in healthcare. …
Canadian medical cannabis company Tilray’s stock surged by over 77 percent in the first three trading days of last week before dropping dramatically by 47.9 percent to close out the…
Article contributed by Carla Smith, Executive Vice President of The Healthcare Information and Management Systems Society (HIMMS) for PharmaBoardroom. Today more Canadians are dying in this crisis than at the height of…
As cannabis in Canada cruises towards legalization, Pharma giants race for patented products. Big Pharma is establishing a significant cannabis presence in Canada with registered patents in advance of…
While many Canadian medical cannabis outfits cover the entire value chain, from research and development through to manufacturing and distribution, others – such as Canopy Health and Tetra Bio-Pharma –…
Valeant Pharmaceuticals has taken the decision to rename itself in an effort to distance the company from a series of pricing scandals that occurred under previous CEO J. Michael Pearson.…
“If you are trying to be everything to everybody, you end up being nothing to no one”—Michael Gorenstein, CEO of The Cronos Group talks to PharmaBoardroom about his unusual career…
With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO…
Bob McLay, vice president and general manager of Sobi in Canada, discusses how innovation and collaboration with regulators and payers are helping Sobi to bring its medicines to Canadians suffering…
See our Cookie Privacy Policy Here
